TY - JOUR
T1 - Characterizing Lymphoma Incidence and Disparities for a Cancer Center Catchment Region
AU - Ayers, Amy A.
AU - Lyu, Lin
AU - Dance, Kaylin
AU - Ward, Kevin C.
AU - Flowers, Christopher R.
AU - Koff, Jean L.
AU - McCullough, Lauren E.
N1 - Funding Information:
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers K24CA208132 and U01CA195568 , and by a Diversity Supplement to U01CA195568 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funding Information:
Dr Flowers has served as a consultant for: Abbvie, Astra Zeneca, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche (unpaid), Gilead, OptumRx, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen, and Spectrum. Related to Dr Flowers’ research, Emory University has received research funding from: Abbvie, Acerta, BeiGene, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, M2Gen, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, and the V Foundation. The remaining authors have stated that they have no conflicts of interest.Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers K24CA208132 and U01CA195568, and by a Diversity Supplement to U01CA195568. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/11
Y1 - 2019/11
N2 - Background: Racial disparities in non-Hodgkin lymphoma (NHL) are not well-elucidated for specific catchment areas, which can influence outcomes. Leveraging regional data from a population-based cancer registry may provide unique opportunities to quantify NHL disparities. Materials and Methods: Using Surveillance, Epidemiology, and End Results (SEER) data for NHL cases diagnosed in Georgia from 2001 to 2015, we examined NHL incidence rates by lymphoma subtype and racial differences in baseline characteristics and outcomes for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Cox regression models identified predictors of overall survival (OS). Results: SEER documented 38,504 NHL cases in Georgia from 2001 to 2015. The age-adjusted incidence rate for NHL in Georgia increased 1.03% per year, and the annual percentage change was 1.72 in blacks compared with 0.84 in whites. Compared with whites, blacks with DLBCL and FL were more likely to be diagnosed at a younger age (DLBCL, 54.1 vs. 65.5 years; P <.0001; FL, 58.4 vs. 64.0 years; P <.0001) and with B symptoms (DLBCL, 44.4% vs. 33.4%; P <.0001; FL, 28.5% vs. 21.4%; P =.004). Across racial categories, age at diagnosis > 60 years, advanced stage, and B symptoms predicted worse OS in DLBCL and FL. Blacks with DLBCL more commonly were diagnosed with stage III/IV disease (55.5% vs. 48.1%; P <.0001) and had worse 5-year relative survival (58.8% vs. 62.3%; P =.01). Conclusions: Regional cancer registry data can be used to define incidence patterns and disparities in outcomes across NHL subtypes to help define key targets for interventions in a catchment area. In a retrospective analysis of 38,504 lymphoma diagnoses in Georgia between 2001 and 2015, we found that, compared with whites, blacks with diffuse large B-cell lymphoma and follicular lymphoma were more likely to present at a younger age and experience B symptoms. Future research utilizing population-based data to address disparities in presentation and outcomes within a catchment area is needed.
AB - Background: Racial disparities in non-Hodgkin lymphoma (NHL) are not well-elucidated for specific catchment areas, which can influence outcomes. Leveraging regional data from a population-based cancer registry may provide unique opportunities to quantify NHL disparities. Materials and Methods: Using Surveillance, Epidemiology, and End Results (SEER) data for NHL cases diagnosed in Georgia from 2001 to 2015, we examined NHL incidence rates by lymphoma subtype and racial differences in baseline characteristics and outcomes for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Cox regression models identified predictors of overall survival (OS). Results: SEER documented 38,504 NHL cases in Georgia from 2001 to 2015. The age-adjusted incidence rate for NHL in Georgia increased 1.03% per year, and the annual percentage change was 1.72 in blacks compared with 0.84 in whites. Compared with whites, blacks with DLBCL and FL were more likely to be diagnosed at a younger age (DLBCL, 54.1 vs. 65.5 years; P <.0001; FL, 58.4 vs. 64.0 years; P <.0001) and with B symptoms (DLBCL, 44.4% vs. 33.4%; P <.0001; FL, 28.5% vs. 21.4%; P =.004). Across racial categories, age at diagnosis > 60 years, advanced stage, and B symptoms predicted worse OS in DLBCL and FL. Blacks with DLBCL more commonly were diagnosed with stage III/IV disease (55.5% vs. 48.1%; P <.0001) and had worse 5-year relative survival (58.8% vs. 62.3%; P =.01). Conclusions: Regional cancer registry data can be used to define incidence patterns and disparities in outcomes across NHL subtypes to help define key targets for interventions in a catchment area. In a retrospective analysis of 38,504 lymphoma diagnoses in Georgia between 2001 and 2015, we found that, compared with whites, blacks with diffuse large B-cell lymphoma and follicular lymphoma were more likely to present at a younger age and experience B symptoms. Future research utilizing population-based data to address disparities in presentation and outcomes within a catchment area is needed.
KW - Diffuse large B-cell lymphoma
KW - Follicular lymphoma
KW - Non-Hodgkin lymphoma
KW - Racial differences
KW - SEER
UR - http://www.scopus.com/inward/record.url?scp=85071694501&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071694501&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2019.06.009
DO - 10.1016/j.clml.2019.06.009
M3 - Article
C2 - 31494062
AN - SCOPUS:85071694501
SN - 2152-2650
VL - 19
SP - 699-708.e5
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 11
ER -